OncoMatch/Clinical Trials/NCT07717437
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
Is NCT07717437 recruiting? Yes, currently enrolling (Sep 2026).
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Must have received: portal and hepatic vein embolization
Patients who have undergone PVE/HVE or technical variations on this procedure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rush University Medical Center · Chicago, Illinois
- Mayo Clinic · Rochester, Minnesota
- Cleveland Clinic · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07717437 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received portal and hepatic vein embolization.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages